132 related articles for article (PubMed ID: 28131548)
1. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel R; Barker HE; Kyula J; McLaughlin M; Dillon MT; Schick U; Hafsi H; Thompson A; Khoo V; Harrington K; Zaidi S
Radiother Oncol; 2017 Mar; 122(3):470-475. PubMed ID: 28131548
[TBL] [Abstract][Full Text] [Related]
2. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
3. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
[TBL] [Abstract][Full Text] [Related]
4. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Walton MI; Eve PD; Hayes A; Valenti MR; De Haven Brandon AK; Box G; Hallsworth A; Smith EL; Boxall KJ; Lainchbury M; Matthews TP; Jamin Y; Robinson SP; Aherne GW; Reader JC; Chesler L; Raynaud FI; Eccles SA; Collins I; Garrett MD
Clin Cancer Res; 2012 Oct; 18(20):5650-61. PubMed ID: 22929806
[TBL] [Abstract][Full Text] [Related]
5. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Chen X; Liu H; Rock C; Buchholz TA; Shumway SD; Skinner HD; Meyn RE
Oncotarget; 2016 Nov; 7(44):71660-71672. PubMed ID: 27690219
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
Dillon MT; Barker HE; Pedersen M; Hafsi H; Bhide SA; Newbold KL; Nutting CM; McLaughlin M; Harrington KJ
Mol Cancer Ther; 2017 Jan; 16(1):25-34. PubMed ID: 28062704
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Lainchbury M; Matthews TP; McHardy T; Boxall KJ; Walton MI; Eve PD; Hayes A; Valenti MR; de Haven Brandon AK; Box G; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2012 Nov; 55(22):10229-40. PubMed ID: 23082860
[TBL] [Abstract][Full Text] [Related]
8. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.
Busch CJ; Kriegs M; Laban S; Tribius S; Knecht R; Petersen C; Dikomey E; Rieckmann T
Radiother Oncol; 2013 Sep; 108(3):495-9. PubMed ID: 23932155
[TBL] [Abstract][Full Text] [Related]
9. Targeted radiosensitization by the Chk1 inhibitor SAR-020106.
Borst GR; McLaughlin M; Kyula JN; Neijenhuis S; Khan A; Good J; Zaidi S; Powell NG; Meier P; Collins I; Garrett MD; Verheij M; Harrington KJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1110-8. PubMed ID: 22981708
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
12. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
13. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
[TBL] [Abstract][Full Text] [Related]
14. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
15. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
16. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
17. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
19. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]